title: [Mucoviscidosis: CFTR mutation-specific therapy: a ray of sunshine in a cloudy sky].
abstract: There is a need to find a cure for pulmonary disease in cystic fibrosis (CF), though full benefit of this approach will be restricted to those patients with well-preserved lungs. The most promising route is currently that of a pharmacological mutation-specific approach aiming at correcting the mechanism by which mutations lead to impairment of chloride conductance across respiratory epithelial cells. In the past 14years, 7 candidate drugs (CPX, 4PBA, gentamicin, PTC124, VX-770 or Ivacaftor, VX-809 or Lumacaftor, and Miglustat) have been investigated in CF patients. A postulate of 14 out of the 15 published studies has been that an effective agent had to improve total chloride secretion as assessed in vivo by nasal potential difference measurements. The present review casts a critical look at these studies. Apparent inconsistencies are discussed as well as possible limitations of nasal potential difference measurements as outcome parameters in these trials. Primarily targeting a mutation carried by less than 2% of French CF patients, the 2 Ivacaftor studies could well be a milestone on the long road toward a cure for CF. However, further data on safety and long-term efficacy are obviously needed and the current price of this medication in the US would make it unaffordable for European patients.
authors.affiliation: Unité de pneumologie pédiatrique et mucoviscidose, cliniques Saint-Luc, université de Louvain, Bruxelles, Belgique. anissa.leonard@uclouvain.be
authors.forename: A
authors.initials: A
authors.lastname: Leonard
authors.forename: T
authors.initials: T
authors.lastname: Leal
authors.forename: P
authors.initials: P
authors.lastname: Lebecque
mesh_terms: D002712:Chlorides / Q000378:metabolism*; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000187:drug effects* / Q000235:genetics* / Q000378:metabolism; D004847:Epithelial Cells / Q000187:drug effects; D019317:Evidence-Based Medicine; D006801:Humans; D009154:Mutation / Q000187:drug effects*; D013542:Sweat / Q000737:chemistry; D016896:Treatment Outcome
chemical_list: D002712:Chlorides; D019005:Cystic Fibrosis Transmembrane Conductance Regulator